Literature DB >> 33298547

G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-κB Signaling Pathway.

Ting Sun1,2, Keqiang Zhang3, Rajendra P Pangeni1, Jun Wu4, Wendong Li1, Yong Du2, Yuming Guo4, Shyambabu Chaurasiya5, Leonidas Arvanitis6, Dan J Raz3.   

Abstract

Potential roles of euchromatic histone methyltransferase 2 (EHMT2 or G9a) in invasion and metastasis are not well understood in non-small cell lung cancer (NSCLC). Here, we investigated the effect and underlying mechanisms of G9a and therapeutic implications of targeting G9a in the invasion and metastasis of NSCLC. Overexpression of G9a significantly enhanced in vitro proliferation and invasion, while knockdown of G9a drastically suppressed in vivo growth and metastasis of A549 and H1299 NSCLC cells. Knockdown or inhibition of G9a significantly decreased the expression of focal adhesion kinase (FAK) protein and activation of FAK pathway. In addition, defactinib, a potent FAK inhibitor, partially abolished the G9a-enhanced invasion in these NSCLC cells. Furthermore, targeting G9a was found to suppress NF-κB transcriptional activity in NSCLC cells through stabilizing NF-κB inhibitor alpha (IκBα), while an NF-κB inhibitor Parthenilide partially abolished the G9a-enhanced FAK activation, which suggests that G9a-enhanced invasion and activation of FAK is mediated by elevated NF-κB activity. Notably, a strong positive correlation between the IHC staining of G9a and phosphorylated FAK proteins was identified in H1299 xenografts and 159 cases of NSCLC tissues (R = 0.408). IMPLICATIONS: The findings of this study strongly demonstrate that G9a may promote invasion and metastasis of NSCLC cells by enhancing FAK signaling pathway via elevating NF-κB transcriptional activity, indicating potential significance and therapeutic implications of these pathways in the invasion and metastasis of NSCLCs that overexpress G9a protein. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33298547      PMCID: PMC8785801          DOI: 10.1158/1541-7786.MCR-20-0557

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation.

Authors:  R J Wozniak; W T Klimecki; S S Lau; Y Feinstein; B W Futscher
Journal:  Oncogene       Date:  2006-06-26       Impact factor: 9.867

Review 2.  A perspective on cancer cell metastasis.

Authors:  Christine L Chaffer; Robert A Weinberg
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

Review 3.  Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity.

Authors:  Alexios Matikas; Dimitrios Mistriotis; Vasilios Georgoulias; Athanasios Kotsakis
Journal:  Crit Rev Oncol Hematol       Date:  2016-12-09       Impact factor: 6.312

4.  Up-regulation of focal adhesion kinase in non-small cell lung cancer.

Authors:  Stephana Carelli; Giorgia Zadra; Valentina Vaira; Monica Falleni; Luca Bottiglieri; Mario Nosotti; Anna Maria Di Giulio; Alfredo Gorio; Silvano Bosari
Journal:  Lung Cancer       Date:  2006-07-13       Impact factor: 5.705

5.  RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas.

Authors:  Georgia Konstantinidou; Giorgio Ramadori; Francesca Torti; Kim Kangasniemi; Rachel E Ramirez; Yiran Cai; Carmen Behrens; Michael T Dellinger; Rolf A Brekken; Ignacio I Wistuba; Adriana Heguy; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Discov       Date:  2013-01-28       Impact factor: 39.397

6.  Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.

Authors:  Ke-Jing Tang; Jerfiz D Constanzo; Niranjan Venkateswaran; Margherita Melegari; Mariya Ilcheva; Julio C Morales; Ferdinandos Skoulidis; John V Heymach; David A Boothman; Pier Paolo Scaglioni
Journal:  Clin Cancer Res       Date:  2016-05-24       Impact factor: 12.531

7.  ING4 induces cell growth inhibition in human lung adenocarcinoma A549 cells by means of Wnt-1/beta-catenin signaling pathway.

Authors:  Xiaomei Li; Limin Cai; Meihua Liang; Yandong Wang; Jing Yang; Yulan Zhao
Journal:  Anat Rec (Hoboken)       Date:  2008-05       Impact factor: 2.064

8.  pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.

Authors:  Kamolrat Thanapprapasr; Adisak Nartthanarung; Duangmani Thanapprapasr; Artit Jinawath
Journal:  PLoS One       Date:  2017-08-28       Impact factor: 3.240

9.  H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression.

Authors:  S P Rowbotham; F Li; A F M Dost; S M Louie; B P Marsh; P Pessina; C R Anbarasu; C F Brainson; S J Tuminello; A Lieberman; S Ryeom; T M Schlaeger; B J Aronow; H Watanabe; K K Wong; C F Kim
Journal:  Nat Commun       Date:  2018-11-19       Impact factor: 14.919

10.  Increased Expression and Activation of FAK in Small-Cell Lung Cancer Compared to Non-Small-Cell Lung Cancer.

Authors:  Frank Aboubakar Nana; Delphine Hoton; Jérôme Ambroise; Marylène Lecocq; Marie Vanderputten; Yves Sibille; Bart Vanaudenaerde; Charles Pilette; Caroline Bouzin; Sebahat Ocak
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

View more
  7 in total

1.  Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.

Authors:  Kwang-Su Park; Yan Xiong; Hyerin Yim; Julia Velez; Nicolas Babault; Prashasti Kumar; Jing Liu; Jian Jin
Journal:  J Med Chem       Date:  2022-06-28       Impact factor: 8.039

Review 2.  Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2.

Authors:  Gareth Chin Khye Ang; Amogh Gupta; Uttam Surana; Shirlyn Xue Ling Yap; Reshma Taneja
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

3.  G9a promotes inflammation in Streptococcus pneumoniae induced pneumonia mice by stimulating M1 macrophage polarization and H3K9me2 methylation in FOXP1 promoter region.

Authors:  Yi Li; Guanhua Li; Li Zhang; Yuechuan Li; Zhan Zhao
Journal:  Ann Transl Med       Date:  2022-05

4.  KRT8 Serves as a Novel Biomarker for LUAD and Promotes Metastasis and EMT via NF-κB Signaling.

Authors:  Hao Chen; Xiaobin Chen; Bo Pan; Chutian Zheng; Liangjie Hong; Weili Han
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

5.  Integrin α3/α6 and αV are implicated in ADAM15-activated FAK and EGFR signalling pathway individually and promote non-small-cell lung cancer progression.

Authors:  Jieqi Zhou; Anqi Wang; Tingting Cai; Yue Li; Wenwen Du; Yang Zhang; Ruochen Zhang; Weijie Zhang; Jianjie Zhu; Yuanyuan Zeng; Jian-An Huang; Zeyi Liu
Journal:  Cell Death Dis       Date:  2022-05-21       Impact factor: 9.685

Review 6.  Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors.

Authors:  Kaibo Guo; Yuqian Feng; Xueer Zheng; Leitao Sun; Harpreet S Wasan; Shanming Ruan; Minhe Shen
Journal:  Front Oncol       Date:  2021-04-16       Impact factor: 6.244

7.  Transcription factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expression.

Authors:  Ting Sun; Keqiang Zhang; Wendong Li; Yunze Liu; Rajendra P Pangeni; Aimin Li; Leonidas Arvanitis; Dan J Raz
Journal:  Cell Commun Signal       Date:  2022-09-19       Impact factor: 7.525

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.